Abstract
Menopause is a universal physiological transition yet one of the most inequitably managed health events globally. In Pakistan and South Asia, women entering menopause face structural healthcare gaps, cultural barriers to care-seeking, provider knowledge deficits, and limited policy attention. With a mean age at natural menopause of approximately 47 years, Pakistani women experience a prolonged postmenopausal period that may amplify cardiovascular, skeletal, and metabolic risks; however, formal menopause care remains available to only a minority of symptomatic women. This narrative review was conducted according to the Scale for the Assessment of Narrative Review Articles (SANRA) framework. Literature searches were performed in PubMed, EMBASE, Scopus, and Google Scholar from 1990 through March 2025. Thirty-five references meeting predefined inclusion criteria were included. The review synthesizes evidence across six domains: vasomotor symptom epidemiology, menopausal hormone therapy (MHT) controversies, cardiovascular risk, osteoporosis burden, sociocultural barriers, and non-hormonal and digital therapeutic approaches. Vasomotor symptom prevalence in South Asian women is comparable to Western estimates of 50 to 74 percent, yet treatment uptake remains low. Postmenopausal osteoporosis affects 20 to 49 percent of Pakistani women, with a substantial burden of osteoporotic fractures. Pakistan also reports a comparatively elevated age-standardized ischemic heart disease mortality-to-prevalence ratio among women, although this finding requires cautious interpretation given heterogeneity in regional datasets. MHT prescribing is influenced by persistent concerns following the Women’s Health Initiative findings, despite evidence supporting its safety when initiated within the appropriate timing window. Fezolinetant and investigational elinzanetant represent emerging non-hormonal options; however, equitable access in LMICs remains unresolved. Pakistan’s Lady Health Worker network and digital platforms such as DoctHERS represent potential pathways for community outreach. Addressing this gap requires coordinated action across policy, clinical training, community engagement, and digital health infrastructure.
References
1. United Nations Population Fund (UNFPA). State of World Population 2023: 8 Billion Lives, Infinite Possibilities. New York (NY): UNFPA; 2023.
2. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 20196;4:5. https://doi.org/10.1186/s41073-019-0064-8
3. Iyer TK, Fiffick AN, Batur P. Nonhormone therapies for vasomotor symptom management. Cleve Clin J Med. 2024;91(4):237-244. https://doi.org/10.3949/ccjm.91a.23067
4. Islam RM, Bell RJ, Rizvi F, Davis SR. Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. Menopause. 2017;24(11):1313-1322. https://doi.org/10.1097/GME.0000000000000896
5. Fang Y, Liu F, Zhang X, et al. Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1767. https://doi.org/10.1186/s12889-024-19280-5
6. Nisar N, Sikandar R, Sohoo NA. Menopausal symptoms: prevalence, severity and correlation with sociodemographic and reproductive characteristics. J Pak Med Assoc. 2015;65(4):409-413.
7. Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28(8):875-882. https://doi.org/10.1097/GME.0000000000001793
8. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028
9. Guo ZQ. Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management. Front Reprod Health. 2025;7:1694240. https://doi.org/10.3389/frph.2025.1694240
10. Gu Y, Han F, Xue M, Wang M, Huang Y. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Womens Health. 2024;24(1):60. https://doi.org/10.1186/s12905-023-02788-0
11. Ang SB, Sugianto SRS, Tan FCJH, et al. Asia-Pacific Menopause Federation Consensus Statement on the Management of Menopause 2024. J Menopausal Med. 2025;31(1):3-11. https://doi.org/10.6118/jmm.25104
12. Shah N, Tariq H, Khan F, Shah N. Prescribing practices of hormone therapy for menopausal females by OBGYN of Pakistan. Pak J Med Sci. 2023;39(1):128-132. https://doi.org/10.12669/pjms.39.1.6176
13. Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Menopause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. https://doi.org/10.1530/EC-21-0537
14. Khalid AA, Rahman AU, Abbas F, Nadeem A. Sex disparities in ischemic heart disease in South Asia: the role of dietary factors. PLOS Glob Public Health. 2025;5(5):e0004600.
15. Bhatti S, Rehman S, Fayyaz S, et al. Burden of cardiovascular disease in women: data from Pakistan's largest cardiac hospital network. NPJ Women's Health. 2025;3:38. https://doi.org/10.1038/s44294-025-00084-w
16. Liang H, Chen S, Shi M, et al. Global epidemiology and burden of osteoporosis among postmenopausal women: insights from the Global Burden of Disease Study 2021. NPJ Aging. 2025;11(1):78. https://doi.org/10.1038/s41514-025-00269-2
17. Khan AH, Jafri L, Ahmed S, Noordin S. Osteoporosis and its perspective in Pakistan: A review of evidence and issues for addressing fragility fractures. Ann Med Surg (Lond). 2018;29:19-25. https://doi.org/10.1016/j.amsu.2018.03.019
18. Zahid FM, Faisal S, Kamal S, et al. Model Selection and Identification of Osteoporosis Risk Factors in Women to Improve Their Healthcare. J Healthc Eng. 2023;2023:3571769. https://doi.org/10.1155/2023/3571769
19. Lowe NM, Ellahi B, Bano Q, Bangash SA, Mitra SR, Zaman M. Dietary calcium intake, vitamin D status, and bone health in postmenopausal women in rural Pakistan. J Health Popul Nutr. 2011;29(5):465-470. https://doi.org/10.3329/jhpn.v29i5.8900
20. Ahmed S, Farooqui AJ, Pradhan NA, et al. Assessing the knowledge, attitude and practice of osteoporosis among Pakistani women: A national social-media based survey. PLoS One. 2023;18(11):e0288057. https://doi.org/10.1371/journal.pone.0288057
21. Williams M. Culturally responsive care for menopausal women. Maturitas. 2024;185:107995. https://doi.org/10.1016/j.maturitas.2024.107995
22. Shorey S, Ng ED. The experiences and needs of Asian women experiencing menopausal symptoms: a meta-synthesis. Menopause. 2019;26(5):557-569. https://doi.org/10.1097/GME.0000000000001269
23. Baghdadi R, Singh N, Gatuguta A. A grounded theory study exploring immigrant Muslim women's perceptions and experiences of menopause, hormone replacement therapy and menopause-related healthcare in the UK. Post Reprod Health. 2025;31(1):33-38. https://doi.org/10.1177/20533691251322823
24. Jadoon AK, Jadoon A, Jadoon SK. Role of socioeconomic status in defining perception of women about menopause-related myths and facts. J South Asian Feder Menopause Soc. 2020;8(1):42-45. https://doi.org/10.5005/jp-journals-10032-1200
25. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200
26. Shaukat A, Mujeeb A, Shahnoor S, Nasser N, Khan AM. Veozah (fezolinetant): a promising non-hormonal treatment for vasomotor symptoms in menopause. Health Sci Rep. 2023;6(10):e1610. https://doi.org/10.1002/hsr2.1610
27. Morga A, Ajmera M, Gao E, et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause. 2024;31(1):68-76. https://doi.org/10.1097/GME.0000000000002281
28. Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239-246. https://doi.org/10.1097/GME.0000000000002138
29. Mahmoud K, Jaramillo C, Barteit S. Telemedicine in low- and middle-income countries during the COVID-19 pandemic: a scoping review. Front Public Health. 2022;10:914423. https://doi.org/10.3389/fpubh.2022.914423
30. Craig A, Lawford H, Miller M, Chen-Cao L, Woods L, Liaw ST, Godinho MA. Use of Technology to Support Health Care Providers Delivering Care in Low- and Lower-Middle-Income Countries: Systematic Umbrella Review. J Med Internet Res. 2025;27:e66288. https://doi.org/10.2196/66288

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Aqsa Akram


